Pomalidomide-based Protacs

Activity depends on the assembled complex containing the cereblon-binding moiety, the protein-of-interest ligand, and the linked target protein. This arrangement positions the target for ubiquitination by the cereblon E3 ubiquitin ligase. Consequently, chemical design must support productive interactions among all three components, not merely strong binding by either individual ligand.

The linker connects the pomalidomide-derived cereblon ligand to the protein-of-interest ligand and helps determine whether the two binding events can produce a productive ternary complex. Changes in linker structure can therefore influence target ubiquitination and degradation. In chemistry studies, linker variation provides a direct way to investigate structure–activity relationships and optimize degrader performance.

A conventional inhibitor generally modulates a protein by occupying or blocking its functional site, whereas a pomalidomide-based PROTAC promotes removal of the target protein itself. Because the degrader acts through ubiquitination followed by 26S proteasome processing, this strategy changes cellular protein abundance rather than only suppressing activity while the compound remains bound.

The pomalidomide-derived moiety provides the connection to cereblon, an E3 ubiquitin ligase involved in tagging proteins for proteasomal processing. Its presence allows the degrader to recruit this cellular machinery while the second ligand engages the selected protein. The resulting molecular architecture links target recognition with ubiquitination, which is necessary for subsequent degradation.

Design begins by selecting a ligand for the protein of interest and a pomalidomide-derived cereblon-binding ligand, then connecting them through a chemical linker. Researchers can vary linker features and other structural elements to examine structure–activity relationships. Candidate molecules are then evaluated for their ability to promote target ubiquitination and reduce target protein abundance.

They are useful when researchers need to test whether removing a protein produces a cellular consequence, rather than merely blocking its activity. This makes them valuable for target validation and for studying proteins that may be difficult to address with conventional inhibitors. Their modular construction also supports systematic structure–activity relationship investigations.

Experiments can connect molecular design with target ubiquitination and loss of the corresponding protein through the 26S proteasome. Such results help establish whether a chosen target ligand, linker, and cereblon-recruiting element form a functional degrader. In broader research programs, these findings can guide therapeutic development for diseases involving difficult-to-drug proteins.